Femasys Inc., an emerging medical device developer of women's healthcare solutions, today announced an agreement with Bayer Yakuhin, Ltd., Osaka, Japan, for exclusive distribution rights in Japan for Femasys' FemVueT Saline-Air Device.  This is the first device that allows physicians to quickly and effectively evaluate with ultrasound a woman's fallopian tubes, a critical component of her fertility assessment.  The FemVue evaluation procedure can be performed reliably and safely (no radiation), in the physician's office or any facility with ultrasound, in a cost-effective and convenient procedure.  Whether performing FemVue as part of an initial fertility work-up or to reconfirm fallopian tube status prior to other procedures, its innovative design allows for easy adoption into any practice.

(Logo: ) "Our partnership with Bayer now provides physicians in Japan access to our FemVue Saline-Air Device for fallopian tube assessment as a first step in infertility diagnosis or as a part of fertility confirmation," stated Kathy Lee-Sepsick, President & CEO of Femasys Inc. "There is no better partner to introduce FemVue to the Japanese market than Bayer and we have ramped production accordingly to support the commercialization efforts underway." Bayer Yakuhin, Ltd., a wholly-owned subsidiary of the Bayer HealthCare Corporation, has marketing authorization from the Ministry of Health, Labor and Welfare (MHLW) to promote FemVue through their world-class sales channel. The FemVue Saline-Air Device has marketing clearance in the United States, Europe, Canada and Japan.  FemVue is currently distributed in the United States by Norgenix, LLC.

ABOUT FEMASYS INC. | Femasys, based in Atlanta, GA, is a privately held corporation committed to developing and manufacturing innovative, minimally-invasive medical devices for women's unique healthcare needs that provide physicians worldwide with cost-effective, non-surgical methods, while offering their patients access to superior technology.

The Company's FemVue Saline-Air Device, a novel, non-radiological method of assessing fallopian tubes, is being globally commercialized through strategic partners.  The Company has other patent pending technologies in the development pipeline with plans to commercialize two additional products this year.

ABOUT BAYER HEALTHCARE | The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries.

ABOUT BAYER YAKUHIN LTD. | Bayer Yakuhin Ltd., headquartered in Osaka, is a healthcare company which combines business activities of Pharmaceuticals, Radiology & Interventional and Animal Health (companion and food animal products).

Pharmaceuticals business is focused on the following areas: Cardiovascular & Neurology, Oncology & Hematology, Women's Health & Dermatology and Ophthalmology. Bayer Yakuhin aims to be one of leading pharmaceutical companies, which responds to Japanese patients' unmet medical needs, with the spirit of Bayer's corporate slogan "Science For A Better Life".

Business Development Contact: Steven Damon, 770.598.6446, Media Contact: Jerry Fink, 770.500.3910, SOURCE Femasys Inc.

-0- 03/22/2012 /Photo: PRN Photo Desk, /Web Site: CO: Femasys Inc.; Bayer Yakuhin, Ltd.; Bayer Healthcare Corporation ST: Georgia Japan IN: HEA MTC MEQ SU: CON WOM ASI LIC PRN -- CL74972 -- 0000 03/22/2012 16:30:00 EDT http://www.prnewswire.c